Heska Corporation (HSKA)

ATHENS, Ga.--(BUSINESS WIRE)--Dalan Animal Health, Inc. (“Dalan”), the biotech company pioneering insect health with the world’s first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical component of agriculture. One-third of the global food supply relies on pollination, and healthy commercial hives are essential to secure high crop yields. However, honeybee colonies are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Overt clinical cases of American Foulbrood are notifiable in the USA and Canada, and the only treatment method to limit the further spread of disease to other colonies relies on the incineration of bees and infected hives and equipment. Tauzer, also a board member of the California State Beekeepers Association, said, “We are excited about the arrival of Dalan's honey bee vaccine. This innovative solution will help honeybees prevent infection, avoid treatments, and focus on other crucial aspects of maintaining our bee's health”. Tauzer plans to sell vaccinated queen bees through his queen-producing operation, Honey Bee Genetics, beginning this year. Queens can be purchased at honeybeegenetics.com Dr. Annette Kleiser, CEO of Dalan Animal Health, emphasized the importance of the vaccine, stating, “Our mission is to protect our pollinators and promote sustainable agriculture. As global population growth and climate change continue, honeybee pollination will be increasingly vital to secure our food supply. This vaccine is a game-changer in safeguarding honeybees, and we're excited to be at the forefront of revolutionizing insect care, which will ultimately impact global food production.” Beekeepers interested in safeguarding their colonies with Dalan's vaccine can visit the website at https://www.dalan.com/contact or call 844-483-2526. The honey bee vaccine, manufactured by Diamond Animal Health (Des Moines, IA), a wholly-owned subsidiary of Heska (NASDAQ: HSKA), will initially be distributed on a limited basis to commercial beekeepers and queen producers. About the vaccine Dalan's vaccine uses killed whole-cell Paenibacillus larvae bacteria and is administered by mixing it into queen feed consumed by worker bees. The vaccine is incorporated into the royal jelly by the worker bees, who then feed it to the queen. The queen ingests the vaccine, and fragments are deposited in her ovaries, providing immunity to the developing larvae. The non-GMO vaccine can be used in organic agriculture, and pivotal efficacy studies have shown its potential to reduce larval death associated with American Foulbrood infections caused by P. larvae. About Dalan Animal Health, Inc Dalan Animal Health (www.dalan.com) is dedicated to preventing diseases that affect invertebrates, increasing profitability and yield for producers worldwide. This platform technology uses transgenerational immune priming, allowing the maternal animal to pass immune modulators (e.g., antigens, anti-microbial molecules) to the next generation larvae before they hatch. Dalan plans to develop vaccines for other honeybee diseases and underserved industries, such as shrimp, mealworms, and insects used in agriculture. The company is headquartered in Athens, Georgia, at the University of Georgia’s Innovation Hub.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corporation (NasdaqCM: HSKA) to Mars, Incorporated. Under the terms of the proposed transaction, shareholders of Heska will receive $120.00 in cash for each share of Heska that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-hska/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Heska (HSKA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.27 per share a year ago.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corporation (NasdaqCM: HSKA) to Mars, Incorporated. Under the terms of the proposed transaction, shareholders of Heska will receive $120.00 in cash for each share of Heska that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-hska/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit ksfcounsel.com.

NEW YORK , April 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Heska Corporation (NASDAQ: HSKA)'s  sale to Mars, Incorporated for $120.00 per share. If you are a Heska shareholder, click here to learn more about your rights and options.

Heska and privately-held Mars have agreed to a buyout offer of $120 per share. This deal underscores the high-growth potential of pet products companies.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Heska Corporation (NASDAQ: HSKA) to Mars, Incorporated for $120.00 per share is fair to Heska shareholders. Halper Sadeh encourages Heska shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Heska and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Heska shareholders; (2) determine whether Mars is underpaying for Heska; and (3) disclose all material information necessary for Heska shareholders to adequately assess and value the merger consideration. On behalf of Heska shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages Heska shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Heska Corporation (NASDAQ:HSKA ) Q4 2022 Earnings Conference Call February 28, 2023 11:00 AM ET Company Participants Jon Aagaard - Investor Relations Kevin Wilson - Chief Executive Officer and President Catherine Grassman - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Erin Wright - Morgan Stanley Ben Haynor - Alliance Global Partners Jim Sidoti - Sidoti & Company Operator Greetings. Welcome to the Heska Corporation Fourth Quarter and Full-Year 2022 Earnings Conference Call.

Heska (HSKA) delivered earnings and revenue surprises of 44.74% and 3.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

One of the more unexpected market bubbles that developed from Covid-related easy money policies was the “pet stock” bubble. As people were stuck at home more often, they were more likely to adopt pets and spend more to keep them healthy.

Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ATHENS, Ga.--(BUSINESS WIRE)--Dalan Animal Health, Inc. (“Dalan”), a biotech company pioneering insect health, announced today that the U.S. Department of Agriculture (USDA) granted a conditional license for vaccination of honeybees against American Foulbrood disease caused by Paenibacillus larvae. Honeybees are a critical component of agriculture. One-third of the global food supply relies on pollination, and healthy commercial hives are essential to secure high crop yields. However, honeybees are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Overt clinical cases of American Foulbrood are notifiable in the USA and Canada, and the only treatment method relies on the incineration of bees and infected hives and equipment. “This is an exciting step forward for beekeepers, as we rely on antibiotic treatment that has limited effectiveness and requires lots of time and energy to apply to our hives,” explained Trevor Tauzer, owner of Tauzer Apiaries and board member of the California State Beekeepers Association. “If we can prevent an infection in our hives, we can avoid costly treatments and focus our energy on other important elements of keeping our bees healthy.” “We are committed to providing innovative solutions to protect our pollinators and promote sustainable agriculture. Global population growth and changing climates will increase the importance of honeybee pollination to secure our food supply. Our vaccine is a breakthrough in protecting honeybees. We are ready to change how we care for insects, impacting food production on a global scale,” said Dr. Annette Kleiser, CEO of Dalan Animal Health. The bacterin was developed by Dalan Animal Health, and is manufactured by Diamond Animal Health (Des Moines, IA), a wholly-owned subsidiary of Heska (“Heska”; NASDAQ: HSKA). “We are grateful for the help and assistance that Diamond has been able to offer – not just in manufacturing development, but also regulatory expertise,” said Kleiser. The USDA has issued the conditional license in the first instance for two years. Dalan will distribute the vaccine on a limited basis to commercial beekeepers and anticipates having the vaccine available for purchase in the United States in 2023. About the vaccine The vaccine, which contains killed whole-cell Paenibacillus larvae bacteria, is administered by mixing it into queen feed which is consumed by worker bees. The vaccine is incorporated into the royal jelly by the worker bees, who then feed it to the queen. She ingests it, and fragments of the vaccine are deposited in her ovaries. Having been exposed to the vaccine, the developing larvae have immunity as they hatch. Pivotal efficacy studies have indicated that oral vaccination of honeybees may reduce larval death associated with American Foulbrood infections caused by P. larvae. The vaccine is non-GMO and can be used in organic agriculture. About Dalan Animal Health, Inc Dalan Animal Health (www.dalan.com) seeks to prevent diseases that affect invertebrates to increase the profitability and yield to producers worldwide. The company’s platform technology uses a transgenerational immune priming approach whereby the maternal animal passes immune modulators (e.g., antigens, anti-microbial molecules) to the next generation larvae before they hatch. The company intends to use this approach to develop vaccines for other honeybee diseases and underserved industries, such as shrimp, mealworms, and insects used in agriculture. The company’s headquarters is in Athens, Georgia, at the University of Georgia’s Innovation Hub.

Heska Corporation (NASDAQ:HSKA ) Q3 2022 Results Conference Call November 8, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - President and CEO Catherine Grassman - EVP and CFO Conference Call Participants Chris Schott - JPMorgan David Westenberg - Piper Semler Elliot Wilbur - Raymond James Ben Haynor - Alliance Global Partners Erin Wright - Morgan Stanley James Sidoti - Sidoti & Company Operator Good day, and welcome to the Heska Corporation Third Quarter 2022 Conference Call. Today's conference is being recorded.

Heska Corp (NASDAQ:HSKA ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - CEO, President Catherine Grassman - EVP & CFO Conference Call Participants David Westenberg - Piper Sandler Elliot Wilbur - Raymond James Ben Haynor - Alliance Global Partners Erin Wright - Morgan Stanley Jim Sidoti - Sidoti & Company Operator Good day, ladies and gentlemen, and welcome to the Heska Corporation Second Quarter 2022 Conference Call. Today's conference is being recorded.

Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio.